The ability of indicaxanthin to inhibit NF-κB signalling in this HFD model is consistent with our previous observations in other inflammatory-related models, where the yellow betalain was shown to counteract inflammation and tumour progression via NF-κB inhibition, both in vivo and in vitro [26,27,28,29,54,55]. The gene discussed is NFKB1; the disease is neoplasm.